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Dear Editor,
We thank Nordstro¨m and colleagues
for their interest in our study. We
shall try to summarize their criticisms
and to answer them point by point.
1. The statement that cerebral glu-
cose increase following lactate
infusion may be due to a shift in
the cell redox state is debatable in
the absence of NADH/NAD ratio
measurement. Lactate can increase
because of anaerobic glycolysis,
due to lack of oxygen, but also—
frequently—when brain oxygen is
normal [1]. In such conditions,
exogenous lactate can then be
converted to pyruvate, which is
subsequently metabolized via the
TCA cycle, a process known as
aerobic glycolysis [2].
2. Lactate oxidation yields 32 mol ATP
vs. 34 mol ATP during glucose oxi-
dation, a small difference. In contrast
to glucose oxidation, lactate oxida-
tion does not require ATP, which is
an advantage in conditions of limited
energy reserves.
3. Abundant evidence shows that
exogenous supplemental lactate
acts as a ‘‘glucose-sparing sub-
strate’’. Semantic debate remains
as to whether lactate might be
described as a ‘‘preferential’’ or
‘‘opportunistic’’ substrate [3].
What is more relevant from the
clinical standpoint is the potential
benefit of sparing cerebral glucose:
since low cerebral microdialysis
(CMD) glucose is frequent after
traumatic brain injury (TBI) and is
associated with worse outcome
[4], increasing CMD glucose dur-
ing the early critical phase of TBI
with lactate therapy clearly
appears beneficial. Directly
increasing glucose delivery to the
brain with glucose infusions can-
not be recommended because it
might lead to hyperglycemia and
hypotonicity, thereby exacerbating
cerebral damage.
4. A positive correlation between
CMD pyruvate and outcome has
been described [4]; therefore the
increase of brain pyruvate during
lactate infusion seems beneficial.
A pattern of elevated lactate-to-
pyruvate ratio with normal to high
pyruvate is not an exclusive hall-
mark of mitochondrial
dysfunction, because it is also
observed during activated cerebral
glycolysis.
5. Finally, using robust mixed-effects
model statistical analysis we found
that all CMD markers, including
CMD glutamate, did not change in
the 6 h previous to the interven-
tion [5]. During lactate therapy
CMD glutamate (that should have
indeed been presented in lmol/L
instead of mmol/L) decreased
almost significantly (p = 0.06).
Since CMD glutamate might rise
dramatically after TBI [4]—and
the failure to remove this excess
glutamate might lead to excito-
toxic damage and cell death—
providing energy in the form of
lactate, by increasing glucose
availability, helps sustain gluta-
mate uptake in astrocytes and
allows neurons to prevent gluta-
mate ‘‘leak’’.
6. The decrease of ICP following
lactate infusion might indeed pri-
marily be due to hypertonic
sodium. Therapy of intracranial
hypertension with hypertonic lac-
tate solutions might therefore exert
favorable anti-edematous and pro-
energetic effects and could be a
valid therapeutic strategy after
TBI.
In summary, we provided con-
vincing data that exogenous
supplemental lactate can be used as a
preferential glucose-sparing substrate
by the injured brain and that hyper-
tonic lactate might improve
neuroenergetics and reduce brain
edema, thereby attenuating secondary
cerebral damage after TBI. These
data constitute robust arguments
against all criticisms by Nordstro¨m
and colleagues. More importantly,
they support clinical investigation to
examine the potential therapeutic
advantages of hypertonic lactate
solutions after brain injury.
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